Sanofi India Limited
Valuation (77/100) does the heavy lifting; financial trend (10/100) is the drag.
Fair valueStocksWizard rates Sanofi India Limited a Hold, scoring 54/100 on our blended model. At ₹3,318 it trades below our blended DCF and relative-multiples fair value of ₹4,195.28, about 26% upside to that estimate — we read it as undervalued by 26%. On 25.2x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 41% below its 52-week high of ₹5,656.18 and 7% above the low of ₹3,097.1. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9. The average analyst target of ₹4,935.67 implies about 49% upside across 3 analysts. It clears 7 of 11 investability checks, with durability 75, valuation 59 and momentum 32 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹3,356.22.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-41.34% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold54Piotroski F-score 6/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- No data: ROE above 15%
- Pass: Low debt (D/E < 0.5): 0.02x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: -12%
- Fail: Earnings growing: -14%
- Pass: Net margin ≥ 10%: 17.5%
- No data: Current ratio > 1.5
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 11.39
- Fail: Piotroski ≥ 7: 6/9
Quarterly results
Annual financials
Shareholding
- Promoter60.6%
- Institutions24.3%
- Public & other15.1%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (17.5%).
- Financially solid — Altman Z 11.39.
Opportunities
- Well off its 52-week high — possible mean-reversion.
- Trades ~26% below our estimated fair value.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
Threats
- Earnings contracting year on year.
About Sanofi India Limited
Sanofi India Limited manufactures and trades pharmaceutical products across diabetes, cardiology, anti-infectives, and central nervous system therapeutic areas in India, Singapore, and internationally. The company markets brands including Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, and Lasix, among others.
Sanofi India Limited — frequently asked questions
Is Sanofi India Limited a buy, hold or sell?
StocksWizard currently rates Sanofi India Limited (SANOFI) a Hold, based on a blended score of 54/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Sanofi India Limited's fair value?
Our blended DCF and relative-valuation model estimates Sanofi India Limited's fair value at about ₹4,195.28, versus a current price of ₹3,318 — roughly 26% upside. On that basis the stock looks undervalued by 26%.
Is Sanofi India Limited financially healthy?
Sanofi India Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9.
How has Sanofi India Limited's share price performed?
Sanofi India Limited is down 3% over three months, and last traded at ₹3,318. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.